Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2018 2
2020 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Transplant-Related Hepatocellular Carcinoma"
Page 1
Complications after Liver Transplant Related to Preexisting Conditions: Diagnosis, Treatment, and Prevention.
Horrow MM, Huynh ML, Callaghan MM, Rodgers SK. Horrow MM, et al. Radiographics. 2020 May-Jun;40(3):895-909. doi: 10.1148/rg.2019190120. Epub 2020 Apr 10. Radiographics. 2020. PMID: 32281901 Review.
Less common preexisting vascular conditions include congenital anatomic variants, atherosclerosis, chronic portal venous thrombosis, splenic artery and variceal steal phenomena, and transarterial embolization (TAE) for hepatocellular carcinoma (HCC). If unappreciate …
Less common preexisting vascular conditions include congenital anatomic variants, atherosclerosis, chronic portal venous thrombosis, splenic …
Research priorities in Fontan-associated liver disease.
Khan S, Aziz H, Emamaullee J. Khan S, et al. Curr Opin Organ Transplant. 2020 Oct;25(5):489-495. doi: 10.1097/MOT.0000000000000803. Curr Opin Organ Transplant. 2020. PMID: 32833705 Review.
There is little known about the epidemiology of FALD, including risk factors for end-organ failure or hepatocellular carcinoma nor a consensus on surveillance guidelines. Furthermore, there is a need to understand the role of heart versus combined heart-liver transp …
There is little known about the epidemiology of FALD, including risk factors for end-organ failure or hepatocellular carcinoma …
Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit.
Su F, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Su F, et al. Gastroenterology. 2016 Feb;150(2):441-53.e6; quiz e16. doi: 10.1053/j.gastro.2015.10.043. Epub 2015 Oct 30. Gastroenterology. 2016. PMID: 26522262
In hepatitis C virus-negative patients, aging trends were driven by increasing proportions of patients with hepatocellular carcinoma or nonalcoholic steatohepatitis. Among transplant registrants, increasing age was associated with increasing mortality before transpl …
In hepatitis C virus-negative patients, aging trends were driven by increasing proportions of patients with hepatocellular carcino …
Big Data in Transplantation Practice-the Devil Is in the Detail-Fontan-associated Liver Disease.
Kim MH, Nguyen A, Lo M, Kumar SR, Bucuvalas J, Glynn EF, Hoffman MA, Fischer R, Emamaullee J. Kim MH, et al. Transplantation. 2021 Jan 1;105(1):18-22. doi: 10.1097/TP.0000000000003308. Transplantation. 2021. PMID: 32639398
Fontan-associated liver disease (FALD) is characterized by progressive hepatic fibrosis in nearly all patients post-Fontan, with the potential to develop cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. A lack of data regarding FALD-relat …
Fontan-associated liver disease (FALD) is characterized by progressive hepatic fibrosis in nearly all patients post-Fontan, with the potenti …
Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K, Ioannou GN. Berry K, et al. Gastroenterology. 2015 Sep;149(3):669-80; quiz e15-6. doi: 10.1053/j.gastro.2015.05.025. Epub 2015 May 27. Gastroenterology. 2015. PMID: 26021233
BACKGROUND & AIMS: Patients with T2 hepatocellular carcinoma (HCC) can obtain an exception that allows them to undergo liver transplantation with much lower actual Model for End-Stage Liver Disease (MELD) scores than patients without HCC. ...
BACKGROUND & AIMS: Patients with T2 hepatocellular carcinoma (HCC) can obtain an exception that allows them to undergo liv …
Frailty as Tested by Gait Speed Is a Risk Factor for Liver Transplant Respiratory Complications.
Salim TI, Nestlerode LC, Lucatorto EL, Wasserman TL, Din HA, Landsittel DP, Tevar AD, Johnson JT, Duarte-Rojo A, Dunn MA. Salim TI, et al. Am J Gastroenterol. 2020 Jun;115(6):859-866. doi: 10.14309/ajg.0000000000000609. Am J Gastroenterol. 2020. PMID: 32235146
We hypothesized that frailty or sarcopenia could identify the risk for common serious transplant-related adverse respiratory events. METHODS: For 107 patients (74 men, 33 women) transplanted over 1 year, we measured frailty with gait speed, chair stands, and Karnofs …
We hypothesized that frailty or sarcopenia could identify the risk for common serious transplant-related adverse respiratory e …
Retransplant as Rescue Treatment for ABO-Compatible Living-Donor Liver Transplant Related Antibody-Mediated Rejection: A Case Report.
Ho MH, Wu SY, Ou KW, Su TF, Hsieh CB. Ho MH, et al. Exp Clin Transplant. 2018 Apr;16(2):222-226. doi: 10.6002/ect.2015.0308. Epub 2016 Jan 8. Exp Clin Transplant. 2018. PMID: 26742858 Free article. Review.
We encountered a case in which antibody-mediated rejection because of de novo donor specific antibodies against donor human leukocyte antigen developed 6 months after ABO-compatible living-donor liver transplant and was treated with retransplant. A 38-year-old man with hepatitis …
We encountered a case in which antibody-mediated rejection because of de novo donor specific antibodies against donor human leukocyte antige …
The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.
Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M; European Liver and Intestine Transplant Association (ELITA). Cortesi PA, et al. J Viral Hepat. 2018 Jul;25(7):791-801. doi: 10.1111/jvh.12877. Epub 2018 Mar 8. J Viral Hepat. 2018. PMID: 29406608
A decision analytical model was created to simulate the progression of HCV-infected patients listed for decompensated cirrhosis (DCC) or for hepatocellular carcinoma (HCC). Three DAAs treatment strategies were compared: (i) a 12-week course of DAAs prior to transpla …
A decision analytical model was created to simulate the progression of HCV-infected patients listed for decompensated cirrhosis (DCC) or for …